drugset
Drugs / C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs
last change Aug 2020 re-read 2 minutes ago

C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs

Cell therapy

Developed for
HIV infectious disease · Hodgkins lymphoma · non-Hodgkin lymphoma
Investigated by
Fred Hutchinson Cancer Center · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI)

Trials 1 · a red edge is where a trial was stopped

today NCT02343666 · Ph 1
2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02343666 Aug 2016 → Aug 2020 HIV infectious disease, Hodgkins lymphoma, non-Hodgkin lymphoma Fred Hutchinson Cancer Center Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs ClinicalTrials.gov intervention name — accepted as the source's own label NCT02343666 ↗
Modality Cell therapy “gene-modified stem cells” NCT02343666 ↗